2025 annual financial data
NervGen Pharma 2025 Operating cash flow growth
Direct answer
Operating cash flow growth was -15.86%.
Operating income was -25,079,252 CAD and net income was -44,117,305 CAD.
Operating cash flow was -19,499,211 CAD.
Get free NervGen Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 CAD
- Operating income
- -25,079,252 CAD
- Net income
- -44,117,305 CAD
- Operating cash flow
- -19,499,211 CAD